Oxular Limited, a retinal therapeutics development company, announced on Monday that it has named Dr Friedrich (Fritz) Asmus as its new chief medical officer.

In the new role, Dr Asmus will lead all medical, clinical, and regulatory functions to further the company's lead asset, OXU–001 intended for the treatment of diabetic macular oedema and to expedite the development of its early-product pipeline.

Dr Asmus is a board-certified neurologist and pharmacist and, for over 10 years, he has led clinical development programs in the US, Europe, and Asia. He was a key strategic leader in the successful development of alfibercept and other ophthalmic therapies at Bayer Pharma. He has also led development activities for rare ophthalmic diseases at ProQR Therapeutics and jCyte. He holds a private lectureship for Neurology at the University Hospital of Tuebingen, Germany, where he was also deputy chair of the Department of General Neurology.